Stockreport

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Vir Biotechnology, Inc.  (VIR) 
PDF – Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter –– Approximately 50% of participants have compensated cirrhosis – [Read more]